leflunomide has been researched along with Neutropenia in 4 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Neutropenia: A decrease in the number of NEUTROPHILS found in the blood.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This observational study aimed to compare the effectiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or more DMARDs and/or biological agents in a real-world setting." | 7.81 | Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Corominas, H; de la Serna, AR; Díaz-Torné, C; Hernández, MV; Llobet, JM; Magallares, B; Narváez, J; Nolla, JM; Reina, D; Sanmartí, R, 2015) |
| "To estimate the incidence of pancytopenia in patients taking leflunomide with or without methotrexate in Australia." | 7.74 | The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. ( Calcino, LJ; Hill, RL; McEwen, J; Purcell, PM; Riley, CG, 2007) |
| "We present the case of a 62-year-old man with rheumatoid arthritis who developed a leukaemoid reaction and acute respiratory distress syndrome (ARDS) following granulocyte colony-stimulating factor (G-CSF) administration that had been given to treat neutropenia secondary to methotrexate and leflunomide toxicity." | 4.12 | Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed ( Chua, C; Cooke, R; Doig, C; Leung, T, 2022) |
| " This observational study aimed to compare the effectiveness and safety of TCZ in combination with either MTX or leflunomide (LEF) in the treatment of patients with active rheumatoid arthritis (RA) and an inadequate response to one or more DMARDs and/or biological agents in a real-world setting." | 3.81 | Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. ( Corominas, H; de la Serna, AR; Díaz-Torné, C; Hernández, MV; Llobet, JM; Magallares, B; Narváez, J; Nolla, JM; Reina, D; Sanmartí, R, 2015) |
| "To estimate the incidence of pancytopenia in patients taking leflunomide with or without methotrexate in Australia." | 3.74 | The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate. ( Calcino, LJ; Hill, RL; McEwen, J; Purcell, PM; Riley, CG, 2007) |
| " Efficacy and rate of adverse events (AEs) were evaluated during a 24-month period after tocilizumab commencement." | 1.56 | Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis. ( Aalto, K; Backström, M; Grönlund, MM; Kröger, L; Markula-Patjas, K; Putto-Laurila, A; Remes-Pakarinen, T; Vähäsalo, P, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Doig, C | 1 |
| Cooke, R | 1 |
| Chua, C | 1 |
| Leung, T | 1 |
| Grönlund, MM | 1 |
| Remes-Pakarinen, T | 1 |
| Kröger, L | 1 |
| Markula-Patjas, K | 1 |
| Backström, M | 1 |
| Putto-Laurila, A | 1 |
| Aalto, K | 1 |
| Vähäsalo, P | 1 |
| Narváez, J | 1 |
| Díaz-Torné, C | 1 |
| Magallares, B | 1 |
| Hernández, MV | 1 |
| Reina, D | 1 |
| Corominas, H | 1 |
| Sanmartí, R | 1 |
| de la Serna, AR | 1 |
| Llobet, JM | 1 |
| Nolla, JM | 1 |
| McEwen, J | 1 |
| Purcell, PM | 1 |
| Hill, RL | 1 |
| Calcino, LJ | 1 |
| Riley, CG | 1 |
4 other studies available for leflunomide and Neutropenia
| Article | Year |
|---|---|
Acute respiratory distress syndrome precipitated by granulocyte colony-stimulating factor in undiagnosed
Topics: Granulocyte Colony-Stimulating Factor; Humans; Leflunomide; Male; Methotrexate; Middle Aged; Neutrop | 2022 |
Efficacy and safety of tocilizumab in a real-life observational cohort of patients with polyarticular juvenile idiopathic arthritis.
Topics: Adolescent; Alanine Transaminase; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis | 2020 |
Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis.
Topics: Aged; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, Rheumatoid; Dose-Response | 2015 |
The incidence of pancytopenia in patients taking leflunomide alone or with methotrexate.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2007 |